Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial

BACKGROUND: Mogamulizumab was compared with vorinostat in the phase 3 MAVORIC trial (NCT01728805) in 372 patients with relapsed/refractory mycosis fungoides (MF) or Sézary syndrome (SS) who had failed ≥1 prior systemic therapy. Mogamulizumab significantly prolonged progression‐free survival (PFS), w...

Descripción completa

Detalles Bibliográficos
Autores principales: Cowan, R.A., Scarisbrick, J.J., Zinzani, P.L., Nicolay, J.P., Sokol, L., Pinter‐Brown, L., Quaglino, P., Iversen, L., Dummer, R., Musiek, A., Foss, F., Ito, T., Rosen, J‐P., Medley, M.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles and Short Reports Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290719/
https://www.ncbi.nlm.nih.gov/pubmed/34273208
http://dx.doi.org/10.1111/jdv.17523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290719/
https://www.ncbi.nlm.nih.gov/pubmed/34273208
http://dx.doi.org/10.1111/jdv.17523

Ejemplares similares